<DOC>
	<DOCNO>NCT02756819</DOCNO>
	<brief_summary>The purpose study estimate antihypertensive effect azilsartan medoxomil ( Edarbi® ) therapy blood pressure participant overweight obesity routine clinical practice hypertension ( HTN ) treatment Russian Federation Republic Kazakhstan..</brief_summary>
	<brief_title>International Multicenter , Observational , Non-Interventional Prospective Study Azilsartan Medoxomil Participants With Arterial Hypertension Who Are Overweight Obese Russian Federation The Republic Kazakhstan</brief_title>
	<detailed_description>The drug test study call azilsartan medoxomil . Azilsartan medoxomil test treat people hypertension . This study look clinic systolic diastolic blood pressure ( SBP , DBP ) obese participant prescribe azilsartan medoxomil physician . The study enroll approximately 1916 patient . All participant ask take azilsartan medoxomil prescribe physician accord local SmPC . This multi-center trial conduct Russian Federation Republic Kazakhstan . The overall duration study observation approximately 6 month . Participants make multiple visit clinic assign physician accord routine practice , every 3 month .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>1 . Male female participant ≥ 18 year age hypertension ( HTN ) 12 grade . 2 . Participants : newly diagnose arterial HTN inadequately control previously prescribe monotherapy ReninAngiotensinAldosterone System ( RAAS ) blocker inadequately control previously prescribe combination therapy RAAS blocker + diuretic RAAS blocker + calcium antagonist . 3 . The physician decides prescribe Edarbi monotherapy part combination therapy include diuretic calcium antagonist ; 4 . Overweight obesity degree ( body mass index &gt; 25 kg/m^2 ) ; 5 . Is capable understand write informed consent , provide sign write informed consent , agree comply protocol requirement . In case participant blind unable read , inform consent also witness . 1 . Confirmed secondary HTN ; 2 . Contraindications Edarbi respective approve local summary product characteristic ( SmPC ) Edarbi ; 3 . Any reason medical nonmedical character , opinion physician prevent participant participation study . 4 . Is employee family member investigator study site personnel . 5 . Is currently participate clinical trial . Participation noninterventional registry permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>